Atea Pharmaceuticals, Inc. (AVIR) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$35.10M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$48.01M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$45.57M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$41.34M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$35.10M | (m) | (m) | (m) | (m) | -$37.08M* | (m) | $28.15M | (m) | $24.00K |
| 2026-03-31 | Reported | (m) | -$48.01M | (m) | (m) | (m) | (m) | -$46.39M | (m) | $41.13M | (m) | $50.00K |
| 2025-09-30 | Reported | (m) | -$45.57M | (m) | (m) | (m) | (m) | -$40.38M* | (m) | $38.35M | (m) | $196.00K |
| 2025-06-30 | Reported | (m) | -$41.34M | (m) | (m) | (m) | (m) | -$32.87M* | (m) | $32.27M | (m) | $207.00K |
| 2025-03-31 | Reported | (m) | -$39.04M | (m) | (m) | (m) | (m) | -$30.56M | (m) | $29.58M | (m) | $203.00K |
| 2024-09-30 | Reported | (m) | -$37.20M | (m) | (m) | (m) | (m) | -$23.04M* | (m) | $26.16M | (m) | $226.00K |
| 2024-06-30 | Reported | (m) | -$46.92M | (m) | (m) | (m) | (m) | -$42.20M* | (m) | $34.70M | (m) | $243.00K |
| 2024-03-31 | Reported | (m) | -$69.81M | (m) | (m) | (m) | (m) | -$39.87M | (m) | $57.58M | (m) | $231.00K |
| 2023-09-30 | Reported | (m) | -$40.78M | (m) | (m) | (m) | (m) | -$17.59M* | (m) | $28.18M | (m) | $221.00K |
| 2023-06-30 | Reported | (m) | -$35.23M | (m) | (m) | (m) | (m) | -$16.12M* | (m) | $22.06M | (m) | $251.00K |
| 2023-03-31 | Reported | (m) | -$41.57M | (m) | (m) | (m) | (m) | -$29.85M | (m) | $28.95M | (m) | $197.00K |
| 2022-09-30 | Reported | (m) | -$16.28M | (m) | (m) | (m) | $20.00K* | -$21.24M* | (m) | $4.91M | (m) | -$3.83M |
| 2022-06-30 | Reported | (m) | -$32.30M | (m) | (m) | (m) | $1.88M* | -$19.19M* | (m) | $19.86M | (m) | $120.00K |
| 2022-03-31 | Reported | (m) | -$42.17M | (m) | (m) | (m) | $44.00K | -$59.01M | (m) | $29.63M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$22.15M | (m) | $32.81M | (m) | (m) | $22.60M* | (m) | $43.02M | (m) | $6.10M |
| 2021-06-30 | Reported | (m) | $8.69M | (m) | $60.39M | (m) | (m) | -$17.35M* | (m) | $39.80M | (m) | $7.20M |
| 2021-03-31 | Reported | (m) | $30.66M | (m) | $65.98M | (m) | (m) | -$16.84M | (m) | $26.57M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$17.63M | (m) | (m) | (m) | $15.00K* | -$9.48M* | (m) | $13.60M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$10.00M | (m) | (m) | (m) | (m) | -$7.80M* | (m) | $7.75M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$4.04M | (m) | (m) | (m) | (m) | -$4.51M | (m) | $2.82M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$3.77M | (m) | (m) | (m) | (m) | (m) | (m) | $2.41M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$180.89M | (m) | (m) | (m) | (m) | -$132.03M | (m) | $148.02M | (m) | -$6.16M |
| 2024-12-31 | Reported | (m) | -$192.95M | (m) | (m) | (m) | (m) | -$135.50M | (m) | $144.10M | (m) | $925.00K |
| 2023-12-31 | Reported | (m) | -$164.16M | (m) | (m) | (m) | (m) | -$85.39M | (m) | $114.24M | (m) | $1.02M |
| 2022-12-31 | Reported | (m) | -$130.65M | (m) | (m) | (m) | $1.94M | -$120.98M | (m) | $81.94M | (m) | -$3.59M |
| 2021-12-31 | Reported | (m) | $138.38M | (m) | $351.37M | (m) | $4.00K | -$87.00M | (m) | $167.21M | (m) | $17.40M |
| 2020-12-31 | Reported | (m) | -$11.03M | (m) | $48.63M | (m) | $26.00K | $296.73M | (m) | $38.02M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$14.61M | (m) | (m) | (m) | $2.00K | -$12.83M | (m) | $10.17M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$9.48M | (m) | (m) | (m) | $12.00K | -$7.91M | (m) | $6.67M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |